Terns Pharmaceuticals, Inc. (NASDAQ: TERN) Stock Competitors & Peer Comparison

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, VRTX has a market cap of 121.1B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while VRTX trades at $477.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas VRTX's P/E ratio is 25.35. In terms of profitability, TERN's ROE is -0.20%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, TERN is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for TERN.Check VRTX's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, REGN has a market cap of 78.6B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while REGN trades at $762.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas REGN's P/E ratio is 16.71. In terms of profitability, TERN's ROE is -0.20%, compared to REGN's ROE of +0.18%. Regarding short-term risk, TERN is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for TERN.Check REGN's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas VRNA's P/E ratio is -102.80. In terms of profitability, TERN's ROE is -0.20%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, TERN is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for TERN.Check VRNA's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, ARGX has a market cap of 54.3B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while ARGX trades at $853.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas ARGX's P/E ratio is 78.75. In terms of profitability, TERN's ROE is -0.20%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, TERN is less volatile compared to ARGX. This indicates lower risk in terms of short-term price fluctuations for TERN.Check ARGX's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas SGEN's P/E ratio is -57.19. In terms of profitability, TERN's ROE is -0.20%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, TERN is less volatile compared to SGEN. This indicates lower risk in terms of short-term price fluctuations for TERN.Check SGEN's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, RVMDW has a market cap of 42.7B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while RVMDW trades at $9.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas RVMDW's P/E ratio is -2.32. In terms of profitability, TERN's ROE is -0.20%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, TERN is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for TERN.Check RVMDW's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, RVMD has a market cap of 39.9B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while RVMD trades at $187.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas RVMD's P/E ratio is -26.52. In terms of profitability, TERN's ROE is -0.20%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, TERN is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for TERN.Check RVMD's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, ONC has a market cap of 33.8B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while ONC trades at $316.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas ONC's P/E ratio is 70.70. In terms of profitability, TERN's ROE is -0.20%, compared to ONC's ROE of +0.12%. Regarding short-term risk, TERN is less volatile compared to ONC. This indicates lower risk in terms of short-term price fluctuations for TERN.Check ONC's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, ALNY has a market cap of 27.4B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while ALNY trades at $205.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas ALNY's P/E ratio is 37.02. In terms of profitability, TERN's ROE is -0.20%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, TERN is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for TERN.Check ALNY's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, ROIV has a market cap of 24.5B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while ROIV trades at $33.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas ROIV's P/E ratio is -34.86. In terms of profitability, TERN's ROE is -0.20%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, TERN is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for TERN.Check ROIV's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, INCY has a market cap of 24.2B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while INCY trades at $119.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas INCY's P/E ratio is 16.06. In terms of profitability, TERN's ROE is -0.20%, compared to INCY's ROE of +0.30%. Regarding short-term risk, TERN is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for TERN.Check INCY's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, BNTX has a market cap of 22.9B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while BNTX trades at $90.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas BNTX's P/E ratio is -19.61. In terms of profitability, TERN's ROE is -0.20%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, TERN is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for TERN.Check BNTX's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, UTHR has a market cap of 22B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while UTHR trades at $517.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas UTHR's P/E ratio is 19.10. In terms of profitability, TERN's ROE is -0.20%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, TERN is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for TERN.Check UTHR's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, MRNA has a market cap of 21.8B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while MRNA trades at $54.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas MRNA's P/E ratio is -6.73. In terms of profitability, TERN's ROE is -0.20%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, TERN is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for TERN.Check MRNA's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, INSM has a market cap of 21.4B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while INSM trades at $98.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas INSM's P/E ratio is -17.15. In terms of profitability, TERN's ROE is -0.20%, compared to INSM's ROE of -1.30%. Regarding short-term risk, TERN is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for TERN.Check INSM's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas BGNE's P/E ratio is -22.55. In terms of profitability, TERN's ROE is -0.20%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, TERN is less volatile compared to BGNE. This indicates lower risk in terms of short-term price fluctuations for TERN.Check BGNE's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, TERN's ROE is -0.20%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, TERN is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for TERN.Check DNA-WT's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, GMAB has a market cap of 17.7B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while GMAB trades at $28.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas GMAB's P/E ratio is 20.77. In terms of profitability, TERN's ROE is -0.20%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, TERN is less volatile compared to GMAB. This indicates lower risk in terms of short-term price fluctuations for TERN.Check GMAB's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, NBIX has a market cap of 16.8B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while NBIX trades at $166.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas NBIX's P/E ratio is 24.10. In terms of profitability, TERN's ROE is -0.20%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, TERN is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for TERN.Check NBIX's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, JAZZ has a market cap of 15.9B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while JAZZ trades at $252.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas JAZZ's P/E ratio is 19.66. In terms of profitability, TERN's ROE is -0.20%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, TERN is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for TERN.Check JAZZ's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, BBIO has a market cap of 15.7B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while BBIO trades at $80.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas BBIO's P/E ratio is -21.41. In terms of profitability, TERN's ROE is -0.20%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, TERN is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for TERN.Check BBIO's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, ASND has a market cap of 15.1B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while ASND trades at $243.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas ASND's P/E ratio is -100.79. In terms of profitability, TERN's ROE is -0.20%, compared to ASND's ROE of -56.42%. Regarding short-term risk, TERN is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for TERN.Check ASND's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, EXEL has a market cap of 13.3B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while EXEL trades at $53.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas EXEL's P/E ratio is 15.88. In terms of profitability, TERN's ROE is -0.20%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, TERN is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for TERN.Check EXEL's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas KRTX's P/E ratio is -28.09. In terms of profitability, TERN's ROE is -0.20%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, TERN is less volatile compared to KRTX. This indicates lower risk in terms of short-term price fluctuations for TERN.Check KRTX's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, ARWR has a market cap of 11.9B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while ARWR trades at $84.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas ARWR's P/E ratio is -39.37. In terms of profitability, TERN's ROE is -0.20%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, TERN is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for TERN.Check ARWR's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, BMRN has a market cap of 11.6B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while BMRN trades at $60.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas BMRN's P/E ratio is 28.86. In terms of profitability, TERN's ROE is -0.20%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, TERN is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for TERN.Check BMRN's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while TECH trades at $72.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas TECH's P/E ratio is 37.16. In terms of profitability, TERN's ROE is -0.20%, compared to TECH's ROE of +0.05%. Regarding short-term risk, TERN is less volatile compared to TECH. This indicates lower risk in terms of short-term price fluctuations for TERN.Check TECH's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas RNAM's P/E ratio is -17.39. In terms of profitability, TERN's ROE is -0.20%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, TERN is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for TERN.Check RNAM's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, AXSM has a market cap of 11.2B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while AXSM trades at $217.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas AXSM's P/E ratio is -56.92. In terms of profitability, TERN's ROE is -0.20%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, TERN is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for TERN.Check AXSM's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, MDGL has a market cap of 10.8B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while MDGL trades at $467.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas MDGL's P/E ratio is -36.51. In terms of profitability, TERN's ROE is -0.20%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, TERN is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for TERN.Check MDGL's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, SMMT has a market cap of 10.1B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while SMMT trades at $13.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas SMMT's P/E ratio is -8.14. In terms of profitability, TERN's ROE is -0.20%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, TERN is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for TERN.Check SMMT's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, KRYS has a market cap of 10.1B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while KRYS trades at $341.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas KRYS's P/E ratio is 45.60. In terms of profitability, TERN's ROE is -0.20%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, TERN is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for TERN.Check KRYS's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, HALO has a market cap of 9.8B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while HALO trades at $82.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas HALO's P/E ratio is 17.87. In terms of profitability, TERN's ROE is -0.20%, compared to HALO's ROE of +1.26%. Regarding short-term risk, TERN is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for TERN.Check HALO's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while CYTK trades at $77.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas CYTK's P/E ratio is -13.23. In terms of profitability, TERN's ROE is -0.20%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, TERN is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for TERN.Check CYTK's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas RXDX's P/E ratio is -56.47. In terms of profitability, TERN's ROE is -0.20%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, TERN is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for TERN.Check RXDX's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, ABVX has a market cap of 9.2B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while ABVX trades at $124.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas ABVX's P/E ratio is -65.48. In terms of profitability, TERN's ROE is -0.20%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, TERN is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for TERN.Check ABVX's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while NUVL trades at $123.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas NUVL's P/E ratio is -21.79. In terms of profitability, TERN's ROE is -0.20%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, TERN is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for TERN.Check NUVL's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, CRNX has a market cap of 8.8B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while CRNX trades at $83.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas CRNX's P/E ratio is -16.28. In terms of profitability, TERN's ROE is -0.20%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, TERN is less volatile compared to CRNX. This indicates lower risk in terms of short-term price fluctuations for TERN.Check CRNX's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, PTGX has a market cap of 8.8B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while PTGX trades at $136.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas PTGX's P/E ratio is -75.49. In terms of profitability, TERN's ROE is -0.20%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, TERN is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for TERN.Check PTGX's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas IMGN's P/E ratio is -111.55. In terms of profitability, TERN's ROE is -0.20%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, TERN is less volatile compared to IMGN. This indicates lower risk in terms of short-term price fluctuations for TERN.Check IMGN's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, IONS has a market cap of 8.6B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while IONS trades at $51.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas IONS's P/E ratio is -30.10. In terms of profitability, TERN's ROE is -0.20%, compared to IONS's ROE of -1.11%. Regarding short-term risk, TERN is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for TERN.Check IONS's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, PRAX has a market cap of 8.6B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while PRAX trades at $307.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas PRAX's P/E ratio is -23.02. In terms of profitability, TERN's ROE is -0.20%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, TERN is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for TERN.Check PRAX's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, SYRE has a market cap of 8.5B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while SYRE trades at $98.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas SYRE's P/E ratio is -47.27. In terms of profitability, TERN's ROE is -0.20%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, TERN is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for TERN.Check SYRE's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, KYMR has a market cap of 8.5B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while KYMR trades at $103.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas KYMR's P/E ratio is -29.29. In terms of profitability, TERN's ROE is -0.20%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, TERN is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for TERN.Check KYMR's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, ALKS has a market cap of 8.4B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while ALKS trades at $48.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas ALKS's P/E ratio is 52.66. In terms of profitability, TERN's ROE is -0.20%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, TERN is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for TERN.Check ALKS's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas BPMC's P/E ratio is -51.58. In terms of profitability, TERN's ROE is -0.20%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, TERN is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for TERN.Check BPMC's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while APGE trades at $134.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas APGE's P/E ratio is -30.97. In terms of profitability, TERN's ROE is -0.20%, compared to APGE's ROE of -0.33%. Regarding short-term risk, TERN is less volatile compared to APGE. This indicates lower risk in terms of short-term price fluctuations for TERN.Check APGE's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas CERE's P/E ratio is -16.47. In terms of profitability, TERN's ROE is -0.20%, compared to CERE's ROE of -0.72%. Regarding short-term risk, TERN is less volatile compared to CERE. This indicates lower risk in terms of short-term price fluctuations for TERN.Check CERE's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, TGTX has a market cap of 8B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while TGTX trades at $52.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas TGTX's P/E ratio is 17.88. In terms of profitability, TERN's ROE is -0.20%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, TERN is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for TERN.Check TGTX's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, IMVT has a market cap of 7.9B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while IMVT trades at $38.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas IMVT's P/E ratio is -14.46. In terms of profitability, TERN's ROE is -0.20%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, TERN is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for TERN.Check IMVT's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, PCVX has a market cap of 7.8B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while PCVX trades at $54.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas PCVX's P/E ratio is -7.86. In terms of profitability, TERN's ROE is -0.20%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, TERN is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for TERN.Check PCVX's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, IBRX has a market cap of 7.5B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while IBRX trades at $7.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas IBRX's P/E ratio is -8.44. In terms of profitability, TERN's ROE is -0.20%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, TERN is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for TERN.Check IBRX's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas MTSR's P/E ratio is -23.58. In terms of profitability, TERN's ROE is -0.20%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, TERN is less volatile compared to MTSR. This indicates lower risk in terms of short-term price fluctuations for TERN.Check MTSR's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas MRUS's P/E ratio is -17.05. In terms of profitability, TERN's ROE is -0.20%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, TERN is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for TERN.Check MRUS's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, RYTM has a market cap of 6.8B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while RYTM trades at $99.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas RYTM's P/E ratio is -31.71. In terms of profitability, TERN's ROE is -0.20%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, TERN is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for TERN.Check RYTM's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas ACLX's P/E ratio is -28.27. In terms of profitability, TERN's ROE is -0.20%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, TERN is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for TERN.Check ACLX's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, COGT has a market cap of 6.7B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while COGT trades at $38.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas COGT's P/E ratio is -18.45. In terms of profitability, TERN's ROE is -0.20%, compared to COGT's ROE of -0.83%. Regarding short-term risk, TERN is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for TERN.Check COGT's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas RETA's P/E ratio is -66.29. In terms of profitability, TERN's ROE is -0.20%, compared to RETA's ROE of +0.47%. Regarding short-term risk, TERN is less volatile compared to RETA. This indicates lower risk in terms of short-term price fluctuations for TERN.Check RETA's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, MIRM has a market cap of 6.5B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while MIRM trades at $105.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas MIRM's P/E ratio is -7.78. In terms of profitability, TERN's ROE is -0.20%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, TERN is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for TERN.Check MIRM's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, BLTE has a market cap of 6.4B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while BLTE trades at $158.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas BLTE's P/E ratio is -84.82. In terms of profitability, TERN's ROE is -0.20%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, TERN is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for TERN.Check BLTE's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, ERAS has a market cap of 6.3B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while ERAS trades at $18.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas ERAS's P/E ratio is -19.51. In terms of profitability, TERN's ROE is -0.20%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, TERN is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for TERN.Check ERAS's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, CGON has a market cap of 6.3B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while CGON trades at $71.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas CGON's P/E ratio is -30.55. In terms of profitability, TERN's ROE is -0.20%, compared to CGON's ROE of -0.23%. Regarding short-term risk, TERN is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for TERN.Check CGON's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while CNTA trades at $40.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas CNTA's P/E ratio is -22.63. In terms of profitability, TERN's ROE is -0.20%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, TERN is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for TERN.Check CNTA's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, XENE has a market cap of 6.1B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while XENE trades at $62.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas XENE's P/E ratio is -13.33. In terms of profitability, TERN's ROE is -0.20%, compared to XENE's ROE of -0.49%. Regarding short-term risk, TERN is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for TERN.Check XENE's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, LGND has a market cap of 5.8B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while LGND trades at $287.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas LGND's P/E ratio is 34.48. In terms of profitability, TERN's ROE is -0.20%, compared to LGND's ROE of +0.16%. Regarding short-term risk, TERN is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for TERN.Check LGND's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while SRRK trades at $47.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas SRRK's P/E ratio is -13.17. In terms of profitability, TERN's ROE is -0.20%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, TERN is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for TERN.Check SRRK's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, PTCT has a market cap of 5.6B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while PTCT trades at $68.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas PTCT's P/E ratio is -29.19. In terms of profitability, TERN's ROE is -0.20%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, TERN is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for TERN.Check PTCT's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas CDTX's P/E ratio is -19.77. In terms of profitability, TERN's ROE is -0.20%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, TERN is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for TERN.Check CDTX's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, TERN's ROE is -0.20%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, TERN is less volatile compared to ABCM. This indicates lower risk in terms of short-term price fluctuations for TERN.Check ABCM's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas ISEE's P/E ratio is -22.44. In terms of profitability, TERN's ROE is -0.20%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, TERN is less volatile compared to ISEE. This indicates lower risk in terms of short-term price fluctuations for TERN.Check ISEE's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas APLS's P/E ratio is 38.35. In terms of profitability, TERN's ROE is -0.20%, compared to APLS's ROE of +0.40%. Regarding short-term risk, TERN is less volatile compared to APLS. This indicates lower risk in terms of short-term price fluctuations for TERN.Check APLS's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, TVTX has a market cap of 5.2B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while TVTX trades at $55.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas TVTX's P/E ratio is -254.05. In terms of profitability, TERN's ROE is -0.20%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, TERN is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for TERN.Check TVTX's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, DFTX has a market cap of 4.7B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while DFTX trades at $43.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas DFTX's P/E ratio is N/A. In terms of profitability, TERN's ROE is -0.20%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, TERN is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for TERN.Check DFTX's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, DYN has a market cap of 4.6B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while DYN trades at $25.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas DYN's P/E ratio is -7.82. In terms of profitability, TERN's ROE is -0.20%, compared to DYN's ROE of -0.64%. Regarding short-term risk, TERN is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for TERN.Check DYN's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, CRSP has a market cap of 4.6B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while CRSP trades at $47.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas CRSP's P/E ratio is -9.39. In terms of profitability, TERN's ROE is -0.20%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, TERN is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for TERN.Check CRSP's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas FOLD's P/E ratio is -161.00. In terms of profitability, TERN's ROE is -0.20%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, TERN is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for TERN.Check FOLD's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas AKRO's P/E ratio is -14.57. In terms of profitability, TERN's ROE is -0.20%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, TERN is less volatile compared to AKRO. This indicates lower risk in terms of short-term price fluctuations for TERN.Check AKRO's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, DNTH has a market cap of 4.5B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while DNTH trades at $106.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas DNTH's P/E ratio is -25.89. In terms of profitability, TERN's ROE is -0.20%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, TERN is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for TERN.Check DNTH's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas ALPN's P/E ratio is -101.52. In terms of profitability, TERN's ROE is -0.20%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, TERN is less volatile compared to ALPN. This indicates lower risk in terms of short-term price fluctuations for TERN.Check ALPN's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, ACAD has a market cap of 4.4B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while ACAD trades at $25.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas ACAD's P/E ratio is 12.68. In terms of profitability, TERN's ROE is -0.20%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, TERN is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for TERN.Check ACAD's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while CAI trades at $15.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas CAI's P/E ratio is -86.19. In terms of profitability, TERN's ROE is -0.20%, compared to CAI's ROE of +0.06%. Regarding short-term risk, TERN is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for TERN.Check CAI's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, MANE has a market cap of 4.4B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while MANE trades at $105.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas MANE's P/E ratio is -33.36. In terms of profitability, TERN's ROE is -0.20%, compared to MANE's ROE of -0.84%. Regarding short-term risk, TERN is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for TERN.Check MANE's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas OPT's P/E ratio is -1.52. In terms of profitability, TERN's ROE is -0.20%, compared to OPT's ROE of +1.18%. Regarding short-term risk, TERN is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for TERN.Check OPT's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while PRTC trades at $17.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas PRTC's P/E ratio is -3.78. In terms of profitability, TERN's ROE is -0.20%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, TERN is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for TERN.Check PRTC's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, CELC has a market cap of 4.2B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while CELC trades at $86.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas CELC's P/E ratio is -22.15. In terms of profitability, TERN's ROE is -0.20%, compared to CELC's ROE of -2.45%. Regarding short-term risk, TERN is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for TERN.Check CELC's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, EWTX has a market cap of 4.1B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while EWTX trades at $38.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas EWTX's P/E ratio is -23.15. In terms of profitability, TERN's ROE is -0.20%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, TERN is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for TERN.Check EWTX's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas MRTX's P/E ratio is -4.82. In terms of profitability, TERN's ROE is -0.20%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, TERN is less volatile compared to MRTX. This indicates lower risk in terms of short-term price fluctuations for TERN.Check MRTX's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, ELVN has a market cap of 3.9B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while ELVN trades at $54.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas ELVN's P/E ratio is -32.82. In terms of profitability, TERN's ROE is -0.20%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, TERN is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for TERN.Check ELVN's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while CPRX trades at $31.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas CPRX's P/E ratio is 12.30. In terms of profitability, TERN's ROE is -0.20%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, TERN is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for TERN.Check CPRX's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas RYZB's P/E ratio is -57.86. In terms of profitability, TERN's ROE is -0.20%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, TERN is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for TERN.Check RYZB's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas CBAY's P/E ratio is -32.81. In terms of profitability, TERN's ROE is -0.20%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, TERN is less volatile compared to CBAY. This indicates lower risk in terms of short-term price fluctuations for TERN.Check CBAY's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while VKTX trades at $31.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas VKTX's P/E ratio is -7.67. In terms of profitability, TERN's ROE is -0.20%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, TERN is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for TERN.Check VKTX's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, DNLI has a market cap of 3.7B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while DNLI trades at $23.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas DNLI's P/E ratio is -7.99. In terms of profitability, TERN's ROE is -0.20%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, TERN is less volatile compared to DNLI. This indicates lower risk in terms of short-term price fluctuations for TERN.Check DNLI's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, ORKA has a market cap of 3.6B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while ORKA trades at $96.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas ORKA's P/E ratio is -49.75. In terms of profitability, TERN's ROE is -0.20%, compared to ORKA's ROE of -0.26%. Regarding short-term risk, TERN is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for TERN.Check ORKA's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, ADPT has a market cap of 3.6B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while ADPT trades at $22.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas ADPT's P/E ratio is -41.80. In terms of profitability, TERN's ROE is -0.20%, compared to ADPT's ROE of -0.31%. Regarding short-term risk, TERN is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for TERN.Check ADPT's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, ALMS has a market cap of 3.6B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while ALMS trades at $28.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas ALMS's P/E ratio is -7.39. In terms of profitability, TERN's ROE is -0.20%, compared to ALMS's ROE of -0.55%. Regarding short-term risk, TERN is less volatile compared to ALMS. This indicates lower risk in terms of short-term price fluctuations for TERN.Check ALMS's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, RCUS has a market cap of 3.5B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while RCUS trades at $28.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas RCUS's P/E ratio is -8.66. In terms of profitability, TERN's ROE is -0.20%, compared to RCUS's ROE of -0.69%. Regarding short-term risk, TERN is less volatile compared to RCUS. This indicates lower risk in terms of short-term price fluctuations for TERN.Check RCUS's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas SWTX's P/E ratio is -13.78. In terms of profitability, TERN's ROE is -0.20%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, TERN is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for TERN.Check SWTX's competition here

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TERN stands at 4.8B. In comparison, ARQT has a market cap of 3.5B. Regarding current trading prices, TERN is priced at $52.95 on the NASDAQ, while ARQT trades at $26.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TERN currently has a P/E ratio of -51.41, whereas ARQT's P/E ratio is -933.00. In terms of profitability, TERN's ROE is -0.20%, compared to ARQT's ROE of -0.01%. Regarding short-term risk, TERN is less volatile compared to ARQT. This indicates lower risk in terms of short-term price fluctuations for TERN.Check ARQT's competition here